- NCIt
- C8101
Loading cancer entity…
Loading cancer entity…
Clinical trials
1,164 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05631899 | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06504368 | Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors | recruiting | Phase 1 | 32 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 1 | Nov 6, 2025 | clinicaltrials |
| NCT04643418 | Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 81 | MegaPro Biomedical Co. Ltd.INDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04972110 | Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors(ATTACC) | terminated | Phase 1 / Phase 2 | 156 | Repare TherapeuticsINDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT05597839 | Study of DF9001 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 24 | Dragonfly TherapeuticsINDUSTRY | 1 | Oct 29, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT04954599 | Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI | recruiting | Phase 1 / Phase 2 | 126 | Maastricht University Medical CenterOTHER | 3 | Oct 7, 2025 | clinicaltrials |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 23 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05055609 | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | recruiting | Phase 1 | 94 | TretheraINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05114668 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | completed | Phase 1 | 32 | Kazia Therapeutics LimitedINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT00712712 | Morphine After Radiofrequency Ablation of Painful Bone Metastases in Patients With Cancer(MEDOR) | completed | Phase 2 | 78 | Institut BergoniéOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT04169321 | Granzyme B PET Imaging Drug as a Predictor of Immunotherapy Response to Checkpoint Inhibitors | completed | Phase 1 | 13 | Cytosite Biopharma Inc.INDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT03084757 | SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)(SHIVA02) | completed | N/A | 170 | Institut CurieOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02220556 | Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology(CTC-CEC-ADN) | completed | N/A | 360 | Institut CurieOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03410121 | Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy(PACPAC-EPOC) | completed | N/A | 361 | Center Eugene MarquisOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 143 | MacroGenicsINDUSTRY | 4 | Jul 31, 2025 | clinicaltrials |
| NCT02775292 | Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1(NYM) | completed | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04306900 | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers | completed | Phase 1 | 185 | Trishula Therapeutics, Inc.INDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | HutchmedINDUSTRY | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03520075 | Study of ASTX029 in Subjects With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 192 | Taiho Oncology, Inc.INDUSTRY | 4 | Jul 3, 2025 | clinicaltrials |
| NCT00540982 | Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction | completed | Phase 1 / Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03990233 | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | completed | Phase 1 | 100 | OSE ImmunotherapeuticsINDUSTRY | 2 | Jun 26, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT05481502 | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors(PIONEER) | recruiting | N/A | 160 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT04927663 | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression | terminated | Phase 1 | 2 | Rahul AggarwalOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04899505 | Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology(ODORAJA) | completed | — | 27 | Institut CurieOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05759949 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | completed | Phase 1 | 41 | Relay Therapeutics, Inc.INDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT05242822 | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations | terminated | Phase 1 | 54 | Kinnate BiopharmaINDUSTRY | 6 | May 7, 2025 | clinicaltrials |
| NCT02153151 | Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy | completed | — | 21 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT00238355 | Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems | terminated | Phase 2 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | terminated | Phase 1 | 6 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT06462716 | A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06916442 | Granzyme B-targeted PET Imaging Monitoring Tumor Responses to Immunotherapy(GZMB_PET) | not yet recruiting | — | 200 | Zhongnan HospitalOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06897228 | PANK-003 Cell Injection Combined with Standard Adjuvant Chemotherapy After Surgery in Patients with Solid Tumors | recruiting | Phase 1 | 18 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06883539 | A Phase I Study of LXP1788 Injection with Advanced Solid Tumors. | recruiting | Phase 1 | 24 | LaunXP Biomedical Co., Ltd.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 24, 2025source: clinicaltrials